Compare Dollar General Corp. (DG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Zimmer Biomet Holdings Inc — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Dollar General Corp. is the larger of the two by market cap, and Dollar General Corp. pays the higher dividend (1.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DG | ZBH | |
|---|---|---|
Market Cap | $27.42B | $16.95B |
Volume | 2,291,517 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $103.98 |
52-Week Low | $95.94 | $79.58 |
Typical Hold Time | 59 Days | 89 Days |
Enterprise Value | $41.60B | $24.02B |
Dividend Yield | 1.9% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 1.73% today, with a bullish technical signal from moving averages and strong analyst support (55.77% buy ratings). Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.48 exceeding the $2.01 estimate. The company benefits from tariff refunds boosting margins and is expanding delivery via Instacart and scaling its DG Media Network for growth.
The outlook is positive, with a consensus price target of $137.27 implying ~10% upside. Key opportunities include margin recovery initiatives and value-focused merchandising, but risks persist from consumer pressure and competitive discount retail dynamics. Net cash flow improved to $395 million in 2025, though profit margins have narrowed from 7.01% in 2022 to 2.77% in 2025.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
